RO 111464
Alternative Names: RO 11-1464/000Latest Information Update: 08 Nov 2006
At a glance
- Originator Roche
- Class Anti-ischaemics; Antihyperlipidaemics; Small molecules
- Mechanism of Action Apolipoprotein A-I stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Atherosclerosis
Most Recent Events
- 08 Nov 2006 Discontinued - Preclinical for Atherosclerosis in Switzerland (unspecified route)
- 05 Mar 1999 New profile
- 05 Mar 1999 Preclinical development for Atherosclerosis in Switzerland (Unknown route)